The SNaPshot system follows a straightforward protocol and uses infrastructure already existent in most clinical laboratories. This method consists of a multiplexed PCR step, followed by a single-base extension sequencing reaction, in which allele-specific probes interrogate loci of interest and are fluorescently labelled using dideoxynucleotides. These probes are designed to have different sizes and are subsequently resolved by electrophoresis and analysed by an automated DNA sequencer. Thus, the identity of each locus is given by the position of its corresponding fluorescent peak in the spectrum, which is dictated by the length of the extension primer.Detailed view of the single-base extension reaction. The identity of the nucleotide(s) present at each locus is given by two parameters: the molecular weight and the colour of the fluorescently labelled ddNTPs added to the allele specific probes during the extension step. Thus, mutant and wild-type alleles can be distinguished based on the slightly different positions and on the distinct colours of their corresponding peaks. These two factors are used to establish the bins used for automatic data analysis (described in the Supporting Information).

Mutational profiling of 250 cancer specimens is depicted across tumour types according to: their mutational status andthe mutation frequency of individual genes.

Two representative SNaPshot assays illustrate sensitivity evaluation. The section on the left represents the multiplexed panel containing the assay of interest; the middle section is a magnified image of the SNaPshot assay being tested and includes the bins used for automatic allele calling (described in the Supporting Information); and the section on the right represents traditional Sanger sequencing analysis of the same samples. In both cases, the top panel shows genotyping data obtained for normal male genomic DNA (Promega, Madison, WI). In the panels underneath, DNA derived from cancer cell lines harbouring specific mutations was serially diluted against the wild-type genomic DNA (Promega), as specified by the percentage values on the left. Mutant alleles are indicated by arrows, and background signals are marked with asterisks. An in-depth view of sensitivity assessment for these two assays is illustrated in Supporting Information Fig S3. The A427 lung carcinoma cell line was used to detect the KRAS G12D mutation (nucleotide change 35G > A). Sensitivity was ∼3% and the SNaPshot panel includes the following assays: (1) KRAS 35; (2) EGFR 2236_50del R; (3) PTEN 517; (4) TP53 733; (5) FLT3 2503; (6) PIK3CA 3139; (7) NOTCH1 4724 and (8) NOTCH1 4802.The NCI-H1975 lung adenocarcinoma cell line was used to identify the EGFR T790M mutation (nucleotide change 2369C > T). Assay sensitivity was ∼3% and the SNaPshot panel tests for: (1) KRAS 34; (2) EGFR 2235_49del F; (3) EGFR 2369; (4) NRAS 181; (5) PIK3CA 1633; (6) CTNNB1 94 and (7) CTNNB1 121. As can be appreciated in the middle section, decreasing levels of ‘green’ mutant signal (arrows), absent from wild-type DNA (top panel), can be easily distinguished from the nearby ‘red’ background peak (asterisk), which is also found in the assay run on the normal control (top panel). Of note, the EGFR c.2369C assay was designed in the reverse orientation, thus the observed alleles are G (blue) for the wild-type and A (green) for the mutant.

Shown here are three examples of genotyping data obtained using total nucleic acid extracted from normal (top) and tumour (middle) FFPE tissue from the same individual, and a no-DNA negative control (bottom). Of note, the mutant allele (arrow) is only found in the tumour (middle panel). Detection of the EGFR L858R (c.2573T > G) mutation in a case of lung adenocarcinoma. Assays: (1) EGFR 2236_50del F; (2) EGFR 2573; (3) CTNNB1 133; (4) PIK3CA 1624 and (5) NRAS 35.Identification of the KRAS G12V (c.35G > T) mutation in a pancreatic adenocarcinoma. Assays: (1) KRAS 35; (2) EGFR 2236_50del R; (3) PTEN 517; (4) TP53 733; (5) FLT3 2503; (6) PIK3CA 3139; (7) NOTCH1 4724 and (8) NOTCH1 4802.Detection of the BRAF V600E (c.1799T > A) mutation in melanoma. Assays: (1) EGFR 2235_49del R; (2) NRAS 38; (3) BRAF 1799; (4) NRAS 182; (5) PIK3CA 263; (6) TP53 742; (7) CTNNB1 95 and (8) CTNNB1 122.